ApoIII and the treatment and diagnosis of diabetes
US10060935B2 · kind B2 · utility
Assignee
Inventor
Key dates
| Filing date | Jan 18, 2017 |
| Grant date | Aug 28, 2018 |
| Priority date | — |
| Expiry date | Jan 18, 2037 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/52
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The present invention provides methods of identifying candidate compounds for the treatment of type I diabetes comprising contacting pancreatic β cells with an amount of apolipoprotein CIII (“apoCIII”) effective to increase intracellular calcium concentration, in the presence of one or more test compounds, and identifying those test compounds that inhibit an apoCIII-induced increase in intracellular calcium concentration in the pancreatic β cells. The present invention also provides methods for treating patients with type I diabetes comprising administering to the patient an amount effective of an inhibitor of apoCIII to reduce apoCIII-induced increase in intracellular calcium concentration in pancreatic β cells.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.